Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. (Q50988205)

26 March 2018

title

Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. (English)

1 reference

26 March 2018

1 reference

1 reference

1

Ralph A Defronzo

1 reference

26 March 2018

author name string

Rucha J Mehta

series ordinal

2

1 reference

26 March 2018

Joel J Schnure

series ordinal

3

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 April 2013

1 reference

26 March 2018

published in

Hospital Practice

1 reference

26 March 2018

volume

41

1 reference

26 March 2018

issue

2

1 reference

26 March 2018

page(s)

132-147

1 reference

26 March 2018

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Genetic prediction of future type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin Sensitivity and Insulin Binding to Monocytes in Maturity-Onset Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The fundamental drivers of the obesity epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The relationship of insulin response to a glucose stimulus over a wide range of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Nuclear receptors and lipid physiology: opening the X-files

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

PPAR(gamma) and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The effect of pioglitazone on the liver: role of adiponectin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Rosiglitazone RECORD study: glucose control outcomes at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The insulin resistance syndrome: physiological considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Metabolic and molecular basis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Skeletal muscle insulin resistance in normoglycemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated insulin receptor substrate-1 tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Molecular mechanisms of insulin resistance that impact cardiovascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin signaling in the arterial wall

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Dose-response effect of elevated plasma free fatty acid on insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Obesity-induced inflammatory changes in adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones and the liver in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

PPARs: diverse regulators in energy metabolism and metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Secondary failure of metformin monotherapy in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Rosiglitazone decreases albuminuria in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years' data from the South Tees Diabetes Mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones and fracture risk in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Risk of fractures with glitazones: a critical review of the evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therap

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Cohort study of pioglitazone and cancer incidence in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

PROactive: time for a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Thiazolidinediones and Heart Failure: A teleo-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FHP.2013.04.1062

21 January 2018

Identifiers

DOI

10.3810/HP.2013.04.1062

1 reference

26 March 2018

PubMed ID

23680744

1 reference

26 March 2018